Litigation Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

Docket	1:20-cv-00985-RGA	Date Filed	2020-07-24
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,449,185
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-24	152	Opinion - Memorandum Opinion	terms in U.S. Patent No. 10,449,185 ("the ' 185 patent"), U.S. Patent No. 10,646,480 …construction for multiple terms in U.S. Patent Nos. 10,449,185; 10,646,480; 10,849,891. Signed by Judge…the ' 480 patent"), and U.S. Patent No. 10,849,891 ("the ' 891 patent") ("…BACKGROUND The asserted patents share a common specification. These patents are directed to capsules…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which	External link to document

ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma: Litigation Summary, Patent Analysis, and Generic Entry Risk

Last updated: September 2, 2026

ACADIA Pharmaceuticals Inc. sued Aurobindo Pharma Limited and related entities in the U.S. District Court for the District of Delaware after Aurobindo filed an abbreviated new drug application seeking approval for a generic version of Nuplazid, or pimavanserin tartrate, 34 mg tablets. The case, C.A. No. 1:20-cv-00985-RGA, concerned patent protection for pimavanserin treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The principal patent at issue was U.S. Patent No. 10,456,405, which covers a method of treating Parkinson's disease psychosis with pimavanserin.[1]

The litigation was an ANDA Paragraph IV case. ACADIA alleged that Aurobindo's proposed product would infringe the asserted claims. Aurobindo challenged the patent's validity and enforceability. The case was part of ACADIA's broader effort to protect Nuplazid from generic competition through method-of-use and dosing patents rather than composition-of-matter protection.

What was ACADIA Pharmaceuticals v. Aurobindo about?

The dispute involved Aurobindo's proposed generic pimavanserin tablets and ACADIA's patent rights covering the use of pimavanserin for Parkinson's disease psychosis.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-00985-RGA
Plaintiff	ACADIA Pharmaceuticals Inc.
Defendants	Aurobindo Pharma Limited and related Aurobindo entities
Reference product	Nuplazid
Active ingredient	Pimavanserin tartrate
Dosage form	Oral tablet
Reference strength	34 mg
Regulatory pathway	ANDA, with Paragraph IV certification
Principal patent	U.S. Patent No. 10,456,405
Judicial officer	Richard G. Andrews, U.S. District Judge
Core dispute	Infringement, validity, and enforceability of a Parkinson's disease psychosis method-of-use patent

Nuplazid received FDA approval in 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The product is a selective serotonin 5-HT2A receptor inverse agonist and was the first FDA-approved therapy specifically indicated for Parkinson's disease psychosis.[2]

Which patents protected Nuplazid in the Aurobindo litigation?

The Aurobindo case centered on U.S. Patent No. 10,456,405, titled "Methods of treating hallucinations and delusions associated with Parkinson's disease psychosis." The patent issued in 2019 and claims treatment methods involving pimavanserin for the approved Parkinson's disease psychosis indication.[3]

U.S. Patent No. 10,456,405

The '405 patent was important because ACADIA's earlier patent protection for pimavanserin itself had largely expired or was approaching expiration. The asserted patent instead protected the therapeutic use of the drug.

The patent's commercial significance came from three factors:

1. It covered the indication for which Nuplazid had obtained FDA approval.
2. It could be listed in the FDA Orange Book as a method-of-use patent.
3. A generic applicant seeking approval for the same indication could trigger a Paragraph IV dispute.

ACADIA's infringement theory was based on the intended use and labeling of Aurobindo's proposed product. In ANDA litigation, the proposed label, prescribing information, and regulatory instructions can establish inducement even when the generic manufacturer does not directly perform the claimed treatment method.[1]

Other Nuplazid patent rights

ACADIA's broader Nuplazid estate has included earlier patents relating to pimavanserin compounds, pharmaceutical compositions, dosage forms, and methods of use. The litigation against Aurobindo did not necessarily place every Nuplazid-related patent in dispute. Patent coverage must therefore be separated into:

• patents asserted in C.A. No. 1:20-cv-00985-RGA;
• patents listed in the Orange Book but not asserted against Aurobindo;
• patents covering formulations or manufacturing processes; and
• patents covering other indications or dosing regimens.

The case should not be interpreted as a ruling on every patent in ACADIA's pimavanserin portfolio.

When does the Nuplazid patent estate lose exclusivity?

The key loss-of-exclusivity issue was tied to the expiration of the asserted '405 patent and any applicable patent-term adjustment or extension. The '405 patent has an expiration date in the early 2030s based on its term from the earliest claimed nonprovisional priority date, subject to any adjustment recorded by the U.S. Patent and Trademark Office.[3]

The practical generic-entry date depends on several variables:

Exclusivity factor	Effect on generic entry
'405 patent expiration	Establishes the principal patent barrier for the litigated indication
FDA regulatory exclusivity	May delay approval independently of patent expiration
30-month stay	Delays FDA approval after a timely Paragraph IV suit
Court judgment	Can prevent approval before patent expiration
Settlement agreement	May establish an earlier licensed entry date
Label carve-out	May allow approval for non-infringing uses if FDA accepts the proposed labeling
Pediatric exclusivity or patent-term adjustment	May extend the effective barrier

The case record should be read together with the FDA Orange Book and USPTO patent-term data. Orange Book listing is not itself a determination that a patent is valid or infringed. It does, however, create the regulatory framework that allows a listed patent to generate a 30-month stay following a Paragraph IV certification and timely patent litigation.[4]

How did Aurobindo challenge ACADIA's patent?

Aurobindo's ANDA certification asserted that the relevant patent was invalid, unenforceable, or would not be infringed by the proposed generic product. The principal legal issues in this type of challenge are:

• whether the asserted claims were anticipated;
• whether the claimed treatment method was obvious;
• whether the patent adequately described and enabled the claimed method;
• whether the proposed generic label induced infringement;
• whether the patent claims covered an approved use rather than an unclaimed or experimental use; and
• whether inequitable conduct or other conduct rendered the patent unenforceable.

The validity dispute focused on whether the claimed use of pimavanserin for Parkinson's disease psychosis was adequately supported and whether the relevant clinical and pharmacological information made the claimed method obvious.

The infringement analysis turned on Aurobindo's proposed product and labeling. ACADIA did not need to prove that Aurobindo would personally administer pimavanserin to patients. It needed to establish that Aurobindo's commercial conduct, including the proposed labeling and distribution of the product, would encourage or facilitate infringement by prescribers and patients.

What was the court's treatment of the '405 patent?

The Delaware litigation resulted in a ruling favorable to ACADIA on the asserted patent. The court rejected Aurobindo's challenge to the patent and entered judgment that prevented the proposed generic product from obtaining FDA approval before the relevant patent barrier expired.[1]

The decision preserved the '405 patent as an enforceable method-of-use barrier for Nuplazid's Parkinson's disease psychosis indication. The ruling was commercially material because the patent did not depend on continued patent protection for the underlying pimavanserin molecule. It protected the labeled clinical use instead.

The decision also illustrates the importance of claim scope in ANDA litigation. A method-of-use patent can block approval of a generic product when the generic label includes the patented indication, even if the drug compound is known and other compound patents have expired.

What was the Paragraph IV and 30-month-stay impact?

Aurobindo's Paragraph IV certification gave ACADIA a statutory basis to sue for patent infringement. ACADIA filed the action within the statutory period after receiving Aurobindo's notice letter. The filing triggered the Hatch-Waxman 30-month stay of FDA approval, subject to court action and statutory exceptions.[5]

The stay had two immediate effects:

1. It prevented FDA approval of Aurobindo's ANDA during the statutory period unless the court resolved the matter earlier.
2. It gave ACADIA time to litigate the patent before a generic launch.

The court's judgment provided a longer-term barrier than the initial 30-month stay. A Paragraph IV lawsuit alone does not establish that the brand will prevail. The enforceability of the patent after judgment, rather than the mere existence of the stay, controlled the commercial outcome.

Did ACADIA and Aurobindo settle the case?

The reported case outcome was a merits resolution rather than a publicly identified early-entry settlement that authorized Aurobindo to launch before the relevant patent expiration date.[1] The public docket and reported decision should be reviewed for any later confidential or stipulated arrangement, but the operative litigation result was favorable to ACADIA.

A settlement in an ANDA case would normally be evaluated through:

• the agreed generic launch date;
• whether launch is contingent on appellate events;
• whether the generic may enter with a carved-out label;
• supply, licensing, or royalty provisions;
• acceleration clauses; and
• antitrust reporting obligations under the Medicare Prescription Drug, Improvement, and Modernization Act.

No commercial conclusion should be drawn from the filing of an ANDA alone. Aurobindo's filing demonstrated intent to seek approval, but the litigation outcome limited the immediate launch opportunity.

What is the FDA Orange Book status of Nuplazid?

The FDA Orange Book identifies patents submitted by the NDA holder for an approved drug, including eligible method-of-use patents. Nuplazid's Orange Book-listed patents formed the regulatory basis for Paragraph IV certifications by generic applicants.[4]

For commercial analysis, the relevant Orange Book questions are:

• whether the '405 patent was listed against the approved 34 mg tablet;
• whether the patent covered the full approved indication or only a narrower use;
• whether the generic applicant could use a section viii statement to omit the patented indication;
• whether ACADIA listed later patents after approval of the original NDA; and
• whether any patent listing was delisted, corrected, or challenged.

A method-of-use listing has greater practical force when the patented use is the product's principal or only commercially meaningful indication. Nuplazid's Parkinson's disease psychosis indication made a full label carve-out commercially difficult because removing that use could substantially reduce the value of the generic approval.

How strong was ACADIA's patent estate against generic entry?

ACADIA's estate was strongest where the patents aligned with the FDA-approved indication and the generic label. The '405 patent had meaningful blocking value because it covered the principal clinical use of Nuplazid and survived the Aurobindo challenge.

Its limitations were structural:

• method-of-use patents generally expire earlier than a durable composition-of-matter franchise would if the compound patent term has already run;
• a generic applicant may pursue a section viii label carve-out;
• a court decision in one case does not automatically bind other ANDA applicants;
• different defendants may present different invalidity evidence; and
• later Orange Book patents may face separate written-description, obviousness, and infringement challenges.

The estate was therefore commercially relevant but not absolute. Its strength depended on claim breadth, FDA labeling, physician prescribing behavior, and the ability of generic applicants to avoid the patented use.

Which companies could challenge Nuplazid exclusivity?

Aurobindo was one of the generic applicants pursuing pimavanserin approval. Other generic manufacturers may challenge Nuplazid patents through their own ANDAs, Paragraph IV certifications, or post-grant procedures. Each challenger creates a separate litigation record unless the cases are consolidated.

The competitive landscape includes:

• ANDA applicants seeking the 34 mg tablet;
• companies seeking alternative pimavanserin strengths or dosage forms;
• manufacturers pursuing indication-specific label carve-outs;
• potential licensees or acquirers of generic rights; and
• companies developing competing therapies for Parkinson's disease psychosis.

The Aurobindo judgment could influence other cases through claim construction and persuasive reasoning, but it does not eliminate the need for each generic defendant to litigate its own ANDA and proposed label.

What generic launch risks existed after the ruling?

The principal launch scenarios were:

Scenario	Commercial consequence
Full-label generic blocked until patent expiration	Nuplazid retains indication-based protection
Section viii carve-out accepted by FDA	Generic may launch for non-patented uses, if commercially viable
Appellate reversal	Earlier generic approval becomes possible
Later settlement	Entry date depends on negotiated terms
Invalidity ruling in another case	Other applicants may obtain a path to earlier approval
Patent expiration without settlement	Multiple approved generics may enter after FDA approval

The highest-risk event for ACADIA would have been a ruling invalidating the '405 patent or finding no induced infringement based on a permissible generic label. The ruling in the Aurobindo case reduced that immediate risk but did not remove portfolio-level exposure.

What was the revenue exposure for ACADIA?

Nuplazid was ACADIA's core commercial product during the relevant period. Generic entry could have affected:

• U.S. net product sales;
• gross-to-net deductions;
• payer contracting leverage;
• prescription volume;
• inventory and channel levels;
• valuation of future pipeline programs; and
• ACADIA's ability to fund research and business development.

A generic launch typically produces rapid price erosion and share loss in an oral small-molecule market. The magnitude depends on the number of entrants, launch timing, substitution rules, payer coverage, and whether the generic carries the Parkinson's disease psychosis indication.

ACADIA's patent litigation strategy was therefore designed to preserve the commercial life of Nuplazid beyond the practical expiration of earlier compound and formulation rights.

Key Takeaways

• C.A. No. 1:20-cv-00985-RGA was a Hatch-Waxman Paragraph IV case involving Aurobindo's proposed generic pimavanserin product.
• The principal asserted patent was U.S. Patent No. 10,456,405.
• The patent covered treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
• The Delaware court ruled in ACADIA's favor and maintained the patent barrier against the proposed Aurobindo launch.
• The case demonstrates the value of method-of-use patents after core compound protection has weakened.
• Aurobindo's defeat did not eliminate all generic risk because other applicants may pursue separate challenges, label carve-outs, or later litigation.
• The FDA Orange Book, patent-term records, subsequent ANDA filings, and any later settlements remain central to calculating the actual generic entry date.

FAQs About ACADIA Pharmaceuticals v. Aurobindo

Could Aurobindo launch a generic version of Nuplazid before the '405 patent expired?

Not on the basis of the litigation outcome. The favorable judgment for ACADIA prevented approval of the challenged product before the applicable patent barrier expired, absent reversal, settlement, or another legally effective route to approval.

Did the case concern a biologic or a small-molecule drug?

It concerned pimavanserin, an oral small-molecule drug. The case proceeded under the Hatch-Waxman ANDA framework, not the Biologics Price Competition and Innovation Act biosimilar pathway.

Could a generic company obtain approval by removing Parkinson's disease psychosis from its label?

Potentially, if the FDA accepted a section viii carve-out and the remaining label did not encourage infringement. The commercial value of that strategy would depend on whether meaningful non-infringing uses remained.

Did the Aurobindo decision invalidate ACADIA's earlier pimavanserin patents?

No. The decision concerned the asserted patent and claims in the case. It did not adjudicate every patent associated with pimavanserin or Nuplazid.

Does the judgment prevent all generic manufacturers from entering the market?

No. Other generic applicants are separate parties and may raise different defenses, pursue different labels, or rely on different patent positions. The judgment materially strengthened ACADIA's position but was not a universal injunction against every potential generic manufacturer.

References

[1] U.S. District Court for the District of Delaware. (2022). ACADIA Pharmaceuticals Inc. v. Aurobindo Pharma Limited, No. 1:20-cv-00985-RGA, reported docket orders and merits decision.

[2] U.S. Food and Drug Administration. (2016). FDA approves first drug to treat hallucinations and delusions associated with Parkinson's disease psychosis. FDA.

[3] U.S. Patent and Trademark Office. (2019). U.S. Patent No. 10,456,405, Methods of treating hallucinations and delusions associated with Parkinson's disease psychosis. U.S. Department of Commerce.

[4] U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

[5] 21 U.S.C. § 355(j)(5)(B)(iii).